Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.46 |
| ▸ | HTR2C | P28335 | 8/20 | 0.46 |
| ▸ | HTR2B | P41595 | 8/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.31 |
| ▸ | HSD17B4 | P51659 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26123978 | 0.78 | KDM1A (0.33) | — | |
| SCHEMBL3554511 | 0.72 | HTR2C (0.41) | HTR2AHTR2CHTR2BPDK2 | |
| SCHEMBL26124463 | 0.69 | PDK2 (0.37) | HTR2AHTR2CHTR2BPDK2 | |
| SCHEMBL5156710 | 0.67 | GABBR2 (0.41) | CYP3A4 | |
| SCHEMBL17876987 | 0.65 | SMN1; SMN2 (0.46) | PDK2 | |
| SCHEMBL13756894 | 0.63 | HTR2A (1.00) | HTR2AHTR2CHTR2BCYP3A4 | |
| SCHEMBL13756892 | 0.63 | HTR2A (1.00) | HTR2AHTR2CHTR2BCYP3A4 | |
| SCHEMBL9862041 | 0.63 | HSPA5 (0.58) | HTR2AHTR2CHTR2BCYP3A4SIGMAR1 | |
| SCHEMBL1725134 | 0.63 | GABBR2 (0.35) | — | |
| SCHEMBL5251032 | 0.63 | HSPA5 (0.38) | HTR2AHTR2CHTR2BCYP3A4PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572805-B2 | Pyrrolo(oxo)isoquinolines as 5HT ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-20060014777-A1 | Pyrrolo(oxo)isoquinolines as 5HT ligands | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014777-A1 | Pyrrolo(oxo)isoquinolines as 5HT ligands | HTR2B, OPRD1, HTR1B | HTR2A 31/4885HTR2C 17/4885HTR2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.